DESTINA develops assays for the detection of RNA and combinations of RNA and protein biomarkers from biological fluids for research, pharmaceutical development and clinical diagnostics.

DESTINA is focussing its Assay and kit development activities in disease areas where:

      • There is a large opportunity in both pharmaceutical development and clinical diagnostics.
      • There is currently no accurate and effective diagnostic.
      • Where miRNAs represent an opportunity to provide earlier detection and improved assay specificity.

LiverAce 

DESTINA has developed the LiverAce for Liver Injury Failure. The LiverAce solution is the first assay in the world to offer a reliable screening for Liver Injury based on the detection of miRNAs using the ChemiRNA™ Tech. It is an extraction and amplification free test for circulating miRNA-122 using an ultra-sensitive bead-based system.

Features

  1. Absolute quantification of miRNA-122 from body fluids within 2 hours.
  2. High sensitivity and specificity to single-base resolution.
  3. Bead separation and washing steps suitable for automatized equipment.

Procedure

LiverAce Services Powered by Luminex Systems

Luminex-MAGPIX Flexmap 3D

Luminex® MAGPIX® System

FLEXMAP 3D® System

Details

The LiverAce includes DestiNA’s Stabiltech buffer. The assay can be performed from sample preparation, shipment and storage through to analysis at room temperatures.

Comparative study between the gold standard RT-qPCR and LiverAce was undertaken on serum samples from patients with drug induced liver injury. The data show miRNA-122 stability close to 100% during the 28 days (0, 1, 7, 14 and 28) while with the RT-qPCR miRNA numbers decline rapidly at room temperatures.

Request more info